Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Portfolio Pulse from
Phio Pharmaceuticals announced promising results from its clinical study of PH-762, with two patients achieving complete tumor clearance in the second cohort. This development highlights the potential of Phio's INTASYL® siRNA gene silencing technology in treating cutaneous Squamous Cell Carcinoma.
January 13, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals reported promising results from its clinical study of PH-762, with two patients achieving complete tumor clearance. This positive outcome could enhance investor confidence and potentially boost the stock price.
The announcement of complete tumor clearance in two patients is a significant milestone for Phio Pharmaceuticals. This positive clinical outcome could lead to increased investor confidence and a potential rise in stock price, as it demonstrates the effectiveness of their INTASYL® siRNA technology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100